Answers are grounded in this paper and cite their sources.
Timely care is an important aspect of health care quality, particularly for aggressive malignancies like diffuse large B-cell lymphoma (DLBCL). However, the prognostic impact of diagnosis-to-treatment interval (DTI) in DLBCL remains inconclusive. Thus, we evaluated the impact of DTI on survival outcomes using causal inference methods. A total of 2610 DLBCL patients treated with immunochemotherapy from the Lymphoma and Related Diseases Registry were included. Inverse probability of treatment weighting (IPTW) based on propensity scores estimated via generalized boosted models was applied to adjust for differences in adverse prognostic factors between DTI cohorts. The median DTI was 15 days, with an interquartile range of 8–28 days. Patients who received treatment within 14 days had adverse clinical characteristics, including stage III/IV, poor performance status, elevated LDH, B-symptoms, bulk disease, > 1 extranodal sites involved and anaemia. In univariable analyses, shorter DTI (≤ 14 days) was associated with worse overall survival (OS) and progression-free survival (PFS). However, after IPTW adjustment, shorter DTI was significantly associated with improved OS (adjusted hazard ratio = 0.68; 95% CI: 0.52, 0.88). our study suggest that short DTI should be interpreted primarily as a marker of disease severity rather than as an adverse prognostic factor itself.
No takes yet. Share an insight, caveat, or question.
Alem et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: